Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study

Overview of attention for article published in Orphanet Journal of Rare Diseases, February 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#25 of 2,639)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 16 news stories from 10 outlets.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies…

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) announced today that the combined interim…

NEW HAVEN, Conn. --(BUSINESS WIRE) Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data…

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 12 additional news stories.